Anti-leukotriene drugs in modern pediatric practice
https://doi.org/10.21508/1027-4065-2019-64-4-128-132
Abstract
The article summarizes the modern data on the role of leukotrienes in the pathogenesis of allergic diseases of the respiratory tract, in particular, bronchial asthma in children. It determines the role of anti-leukotriene drugs in the treatment of these diseases, the perspectives and key indications for the use of Montelukast in children with bronchial asthma and allergic rhinitis. The article pays attention to highly effective generics, in particular Singlon®.
Keywords
Supporting agencies: The article is published with the support of Gedeon Richter.
About the Authors
Yu. L. Mizernitsky
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
Sh. A. Sulaimanov
International Medical University
Kyrgyzstan
Bishkek
Kyrgyzstan
Bishkek
References
1. Batozhargalova B.Ts., Mizernitskiy Yu.L., Podol’naya M.A. Meta-analysis of the prevalence of asthma-like symptoms and bronchial asthma in Russia (based on ISAAC results). Ros vestn perinatol i pediatr 2016; 61(4): 59–69. DOI: 10.21508/1027-4065-2016-61-4-59-69 (in Russ.).
2. Il’ina N.I., Kurbacheva O.M., Pavlova K.S., Pol’ner S.A. Allergicheskij rinit (AR). Klinicheskiye rekomendatsii Ministerstva Zdravoohraneniya Rossijskoj Federacii. 2018; 23. (in Russ.).
3. Sulaimanov Sh.A., Muratova Zh.K. Epidemiology and comorbidity of allergic diseases in children. Pul’monologiya detskogo vozrasta: problemy i resheniya 2016;16: 179–181. (in Russ.).
4. Bronchial asthma in children. Treatment strategy and prevention. National program (5th edition). Moscow: Original-maket, 2017; 60. (in Russ.). http://nphcd.ru/wp-content/uploads/2017/05/103640_old.pdf
5. Bronchial asthma in children. Editor S.Yu. Kaganov. Moscow: Meditsina, 1999; 368. (in Russ.).
6. Mizernitsky Yu.L. Bronchial asthma. Chronic lung diseases in children. Editors: N.N. Rozinova, Yu.L. Mizernitsky. Moscow: Praktika, 2011; 149–168. (in Russ.).
7. Fedberg W., Kellaway C.H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94(2): 187–226.
8. Mizernitsky Yu.L. Key approaches to the treatment of bronchial asthma in children at the present stage. Pediatriya. Consilium Medicum 2014; 4: 25–27 (in Russ.).
9. Vasilevsky I.V. The use of Montelukast (Singlon) is a new strategy for the treatment of allergic diseases. Meditsinskiye novosti 2013; 12: 36–42. (in Russ.).
10. Csoma Z., Kharitonov S.A., Balint B., Bush A., Wilson N.M., Barnes P.J. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2002; 166: 1345–1349. DOI: 10.1164/rccm.200203-233OC
11. Visitsunthorn N., Chirdjirapong V., Santadilog S., Pajarn P., Jirapongsananuruk O., Komoltri C., Vichyanon P. The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6–13 years. Asian Pac J Allergy Immunol 2011; 29(2): 127–133.
12. Marinich V.V., Mizernitsky Yu.L. Bronchospasm of physical activity in adolescent athletes. Pul’monologiya detskogo vozrasta: problemy i resheniya. Editor Yu.L. Mizernitsky. Moscow: MEDPRAKTIKA-M, 2015; 15: 217–221. (in Russ.).
13. Pauwels R.A., Joos G.F., Kips J.C. Leukotrienes as therapeutic target in asthma. Allergy 1995; 50: 615–622.
14. Barnes N.C. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 73–76. DOI: 10.1164/ajrccm.161.supplement_1.ltta-15
15. Bisgaard H., Zielen S., Garcia-Garcia M.L., Johnston S.L., Gilles L., Menten J. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171(4): 315–322. DOI: 10.1164/rccm.200407-894OC
16. Knorr B., Franchi L.M., Bisgaard H., Vermeulen J.H., LeSouef P., Santanello N. et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108(3): E48. DOI: 10.1542/peds.108.3.e48
17. Scadding G.W., Scadding G.K. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol 2010; 10(4): 370–376. DOI: 10.1097/ACI.0b013e32833bfa20.
18. Wahn U., Dass S.B. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther 2008; 30 Spec No: 1026–1035. DOI: 10.1016/j.clinthera.2008.05.018
19. Geppe N.A., Farber I.M. The use of montelukast leukotriene receptor antagonist for the treatment of bronchial asthma in children during the first years of life. Pul’monologiya (Russian Pulmonology) 2009; 5: 113–118 (in Russ.).
20. Mizernitsky Yu.L. Anti-leukotrienes in the treatment of bronchial asthma in children (expected and real success). Meditsinskij sovet (Medical Council) 2014; 14: 46–49 (in Russ.).
21. Zhernosek V.F., Voytovich T.N., Pivovarova N.P., Gaganova N.V. Safety and tolerability of montelukast (Singlon®) in children 6–14 years in controlling mild persistent asthma. International reviews: clinical practice and health 2015; 1: 65–73.
22. Henderson W.R. Jr, Chiang G.K.S., Tien Y.-T., Chi E.Y. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718–728. DOI: 10.1164/rccm.200501-088OC
23. Pizzichini E., Leff J.A., Reiss T.F., Hendeles L., Boulet L.P., Wei L.X. et al. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J 1999; 14: 12–18.
24. Knorr B., Matz J., Bernstein J.A., Nguyen H., Seidenberg B.C., Reiss T.F., Becker A. Montelukast for chronic asthma in to children: a randomized trial. Pediatric Montelukast Study Group. JAMA 1998; 279(15): 1181–1186.
25. Massingham K., Fox S., Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care 2014; 28(1): 51–62. DOI: 10.1016/j.pedhc.2012.11.005
26. Stanford R.H., Shah M., Chaudhari S.L. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast inchildren with asthma aged 4 to 11 years. Open Respir Med J 2012; 6: 37–43. DOI: 10.2174/1874306401206010037
27. Adelsberg J., Philip G., Pedinoff A.J., Meltzer E.O., Ratner P.H., Menten J. et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003; 58: 1268–1276.
Review
For citations:
Mizernitsky Yu.L., Sulaimanov Sh.A. Anti-leukotriene drugs in modern pediatric practice. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2019;64(4):128-132. (In Russ.) https://doi.org/10.21508/1027-4065-2019-64-4-128-132
Views:
2262
Email this article 